Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Sangamo Therapeutics is a genomic medicine company specializing in gene regulation and editing technologies. Its core focus includes developing epigenetic therapies and innovative AAV capsids for neurological diseases, as well as gene therapies for rare conditions like Fabry disease and hemophilia A. The company leverages zinc finger platforms and proprietary delivery systems to create targeted, potentially curative treatments for serious genetic and neurodegenerative disorders.
This description was generated via AI from an annual report. Updated about 1 year ago.